Antiviral Potential of the Silkworm Deoxynojirimycin against Hepatitis B Virus

Over 350 million people worldwide are chronic carriers of hepatitis B virus (HBV). Chronic viral infections of the liver can progress to cirrhosis, which may ultimately lead to hepatic failure or the development of hepatocellular carcinoma. There are two antiviral drugs on the market approved for cl...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Industrial Entomology 2003, 7(2), , pp.139-144
Main Authors: You, Jung-Eun, Seong, Su-Il, Kim, Young-Ho
Format: Article
Language:Korean
Subjects:
1-Deoxynojirimycin
1-DNJ
HBV
HepG2.2.15
Priming reaction
Silkworm
Transgenic mouse
농학
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Over 350 million people worldwide are chronic carriers of hepatitis B virus (HBV). Chronic viral infections of the liver can progress to cirrhosis, which may ultimately lead to hepatic failure or the development of hepatocellular carcinoma. There are two antiviral drugs on the market approved for clinical management of chronic HBV infections; interferon-alpha and the nucleoside analog lamivudine. However, they showed adverse side-effects. In the rational drug design for such therapies we would like to utilize antiviral drugs that inhibit the HBV replication in the liver. Investigation of natural extracts of silkworm exhibiting antiviral potential was held in the functional HBV polymerase activity and the release of virion particle in the HepG2.2.15 cell lines. HBV-producing transgenic mouse fed with silkworm DNJ molecule was shown as an inhibitor of serum HBV particles. We could represent this DNJ molecule as an antiviral potential complementing conventional therapies after preclinical tests against WHBV-infected animal model, woodchuck.
ISSN:1598-3579
2586-4785